DENND11

Across TCGA pan-cancer cohorts, DENND11 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated DENND11 data layer compared with 20 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher DENND11 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated DENND11 expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

LUAD, PDAC, and CCRCC are the cancer types where DENND11 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Tertile	III,IV	0.289	0.855	.022	9	view →
PDAC	OS	Tertile	All	0.649	0.403	.032	7	view →
CCRCC	DFS	Median	III,IV	0.955	0.774	.018	5	view →
LSCC	DFS	Tertile	II,III,IV	0.304	1.000	.006	4	view →
GBM	DFS	Median	All	0.447	0.296	.036	2	view →
HNSC	DFS	Tertile	III,IV	0.900	1.000	.037	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

DENND11–LUAD (DFS)

Open the LUAD breakdown →